Botulinum Toxin Use in Neurourology

Area of Science:

• Neurourology
• Urology
• Pharmacology

Background:

• Botulinum toxin A (BTX-A) has significantly advanced neurogenic lower urinary tract dysfunction (NLUTD) treatment over 30 years.
• Initially used for detrusor sphincter dyssynergia, BTX-A is now primarily administered as intradetrusor injections for neurogenic detrusor overactivity (NDO).
• BTX-A is the gold-standard for NDO refractory to anticholinergics, supported by high-level evidence.

Purpose of the Study:

• To review recent advancements in BTX-A applications within neurourology.
• To discuss novelties in BTX-A formulations, injection techniques, and treatment strategies for NDO.

Main Methods:

• Review of current literature and clinical practices regarding BTX-A in neurourology.
• Analysis of evidence supporting different BTX-A formulations and injection techniques.
• Exploration of emerging trends and future directions in BTX-A therapy for NDO.

Main Results:

• OnabotulinumtoxinA is licensed in the US and Europe, supported by extensive RCTs.
• AbobotulinumtoxinA also demonstrates efficacy supported by high-level evidence.
• Innovations include BTX-A switching as a rescue therapy and refined injection techniques (e.g., trigonal injections).

Conclusions:

• BTX-A remains a cornerstone therapy for NDO, with ongoing research expanding its utility.
• Newer formulations and techniques are improving treatment outcomes and patient management.
• Further investigation into long-term efficacy, failure management, and potential new indications like urethral sphincter injections is warranted.